This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Trentin, L. Articles by Semenzato, G. Search for Related Content PubMed PubMed Citation Articles by Trentin, L. Articles by Semenzato, G.

B Lymphocytes from Patients with Chronic Lymphoproliferative Disorders Are Equipped with Different Costimulatory Molecules¹

Department of Clinical and Experimental Medicine, Padua University School of Medicine [L. T., R. Z., R. S., M. F., A. C., A. P., M. S., U. B., M. B., F. A., C. A., G. S.], and Division of Hematology, Vicenza Hospital [L. T., R. Z.], 35128 Padua, Italy

Several costimulatory molecules play a key role in the differentiation of B lymphocytes and in T-B-cell interactions. In this study, we addressed the question of whether different receptors and counter-receptors may be expressed on malignant B lymphocytes from chronic B-cell malignancies. Using flow cytometry and reverse transcription PCR analyses, the expression of molecules belonging to the tumor necrosis factor receptor (TNFR) and tumor necrosis factor ligand (TNFL) families, as well as the expression of CD80 and CD86 molecules, was analyzed in normal B cells and in different chronic lymphoproliferative disorders of B-cell type, including B-cell chronic lymphocytic leukemia (CLL), mantle cell lymphoma, hairy cell leukemia (HCL), and HCL variant.

Different patterns of expression of TNFR and TNFL superfamily molecules were demonstrated among B-cell malignancies. In particular, CD40 was commonly observed on all B cells (both tumor and normal), whereas its ligand (CD40L), which is usually undetectable on resting normal B lymphocytes, was expressed in CLL and HCL but not in other chronic lymphoproliferative disorders. CD27 was not shown in normal B cells, although it was present in all malignancies and with particularly high density in mantle cell lymphoma. CD70 was widely distributed on tumor B lymphocytes, but not on the CD5+ normal counterpart. CD30 was strongly expressed in HCL variant and weakly in B-cell CLL, whereas its ligand showed a wide pattern of expression, including all neoplastic and normal B cells. TNFR II (CD120b) and CD80 were distributed on neoplastic B cells from all groups, usually at an intermediate to high degree of intensity, whereas the CD86 molecule was present at lower intensity than CD80. Finally, reverse transcription PCR analysis confirmed the presence of CD40L, CD30, and CD30L mRNAs in those B cells expressing the corresponding membrane-bound proteins at low density.

Our data indicate that TNFR and TNFL molecules are of use clinically both in differentiating B-cell malignancies from the normal counterpart (i.e., CD27, CD70, CD40L, CD30, and CD80) and in defining different chronic B-cell disorders (i.e., CD40L, CD27, and CD30). Interestingly, the observation that several receptors and their ligands (i.e., CD40/CD40L, CD30/CD30L, and CD27/CD70) can be expressed on the same cell suggests that these molecules play a role in initiating and maintaining the neoplastic process by mediating B-T and B-B interactions.

¹ This work was supported by the Italian Association for Cancer Research (Milan, Italy), by the National Research Council (Rome, Italy), Special Project on Clinical Applications of Oncological Research, and by the Ministero dell'Università e Ricerca Scientifica e Tecnologica (Rome, Italy). M. F. is the recipient of a fellowship from the Italian Association for Cancer Research (Milan, Italy), and R. S. is the recipient of a fellowship from the Ministero della Sanità, Istituto Superiore di Sanità (Rome, Italy).

² Present address: Cornell University Medical College, Department of Pathology, Division of Molecular Immunology, 1300 York Avenue, New York, NY 10021.

³ To whom requests for reprints should be addressed, at Università di Padova, Dipartimento di Medicina Clinica e Sperimentale, Via Giustiniani 2, 35128 Padua, Italy. Phone: 39-49-821-2298 or 39-49-821-2299; Fax: 39-49-875-4179.

Received 6/11/97. Accepted 9/ 5/97.

This article has been cited by other articles:

				R. N. Damle, S. Temburni, C. Calissano, S. Yancopoulos, T. Banapour, C. Sison, S. L. Allen, K. R. Rai, and N. Chiorazzi CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells Blood, November 1, 2007; 110(9): 3352 - 3359. [Abstract] [Full Text] [PDF]

				B. F. Israel, M. Gulley, S. Elmore, S. Ferrini, W.-h. Feng, and S. C. Kenney Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas Mol. Cancer Ther., December 1, 2005; 4(12): 2037 - 2044. [Abstract] [Full Text] [PDF]

				M. Hammarsund, M. Lerner, C. Zhu, M. Merup, M. Jansson, G. Gahrton, H. Kluin-Nelemans, S. Einhorn, D. Grander, O. Sangfelt, et al. Disruption of a novel ectodermal neural cortex 1 antisense gene, ENC-1AS and identification of ENC-1 overexpression in hairy cell leukemia Hum. Mol. Genet., December 1, 2004; 13(23): 2925 - 2936. [Abstract] [Full Text] [PDF]

				L. Trentin, A. Cabrelle, M. Facco, D. Carollo, M. Miorin, A. Tosoni, P. Pizzo, G. Binotto, L. Nicolardi, R. Zambello, et al. Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas Blood, July 15, 2004; 104(2): 502 - 508. [Abstract] [Full Text] [PDF]

				A. Younes and M. E. Kadin Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy J. Clin. Oncol., September 15, 2003; 21(18): 3526 - 3534. [Abstract] [Full Text] [PDF]

				G. Munzert, D. Kirchner, H. Stobbe, L. Bergmann, R. M. Schmid, H. Dohner, and H. Heimpel Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis Blood, November 15, 2002; 100(10): 3749 - 3756. [Abstract] [Full Text] [PDF]

				R. N. Damle, F. Ghiotto, A. Valetto, E. Albesiano, F. Fais, X.-J. Yan, C. P. Sison, S. L. Allen, J. Kolitz, P. Schulman, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes Blood, May 13, 2002; 99(11): 4087 - 4093. [Abstract] [Full Text] [PDF]

				B. F. Israel, R. J. Pickles, D. M. Segal, R. D. Gerard, and S. C. Kenney Enhancement of Adenovirus Vector Entry into CD70-Positive B-Cell Lines by Using a Bispecific CD70-Adenovirus Fiber Antibody J. Virol., June 1, 2001; 75(11): 5215 - 5221. [Abstract] [Full Text]

				R. Zambello, L. Trentin, M. Facco, M. Siviero, S. Galvan, F. Piazza, A. Perin, C. Agostini, and G. Semenzato Analysis of TNF-receptor and ligand superfamily molecules in patients with lymphoproliferative disease of granular lymphocytes Blood, July 15, 2000; 96(2): 647 - 654. [Abstract] [Full Text] [PDF]

				R. R. Furman, Z. Asgary, J. O. Mascarenhas, H.-C. Liou2, and E. J. Schattner Modulation of NF-{kappa}B Activity and Apoptosis in Chronic Lymphocytic Leukemia B Cells J. Immunol., February 15, 2000; 164(4): 2200 - 2206. [Abstract] [Full Text] [PDF]

				T. Decker, F. Schneller, T. Sparwasser, T. Tretter, G. B. Lipford, H. Wagner, and C. Peschel Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells Blood, February 1, 2000; 95(3): 999 - 1006. [Abstract] [Full Text] [PDF]

				C. Knorr, C. Amrehn, H. Seeberger, A. Rosenwald, S. Stilgenbauer, G. Ott, H.-K. Muller Hermelink, and A. Greiner Expression of Costimulatory Molecules in Low-Grade Mucosa-Associated Lymphoid Tissue-Type Lymphomas in Vivo Am. J. Pathol., December 1, 1999; 155(6): 2019 - 2027. [Abstract] [Full Text] [PDF]

				A. C. Grammer, R. D. McFarland, J. Heaney, B. F. Darnell, and P. E. Lipsky Expression, Regulation, and Function of B Cell-Expressed CD154 in Germinal Centers J. Immunol., October 15, 1999; 163(8): 4150 - 4159. [Abstract] [Full Text] [PDF]

				R. N. Damle, T. Wasil, F. Fais, F. Ghiotto, A. Valetto, S. L. Allen, A. Buchbinder, D. Budman, K. Dittmar, J. Kolitz, et al. Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia Blood, September 15, 1999; 94(6): 1840 - 1847. [Abstract] [Full Text] [PDF]

				D. Saverino, C. Tenca, D. Zarcone, A. Merlo, A. M. Megiovanni, M. T. Valle, F. Manca, C. E. Grossi, and E. Ciccone CTLA-4 (CD152) Inhibits the Specific Lysis Mediated by Human Cytolytic T Lymphocytes in a Clonally Distributed Fashion J. Immunol., January 15, 1999; 162(2): 651 - 658. [Abstract] [Full Text] [PDF]

				L. van de Corput, H. C. Kluin-Nelemans, M. G.D. Kester, R. Willemze, and J.H. F. Falkenburg Hairy Cell Leukemia-Specific Recognition by Multiple Autologous HLA-DQ or DP-Restricted T-Cell Clones Blood, January 1, 1999; 93(1): 251 - 259. [Abstract] [Full Text] [PDF]

				E. J. Schattner, J. Mascarenhas, I. Reyfman, M. Koshy, C. Woo, S. M. Friedman, and M. K. Crow Chronic Lymphocytic Leukemia B Cells Can Express CD40 Ligand and Demonstrate T-Cell Type Costimulatory Capacity Blood, April 15, 1998; 91(8): 2689 - 2697. [Abstract] [Full Text] [PDF]